Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
In this study the effectiveness of degarelix, a long acting GnRH antagonist administered in a
unique administration of 20 mg the first day of menstrual cycle, to prevent ovarian
hyperstimulation syndrome (OHSS) in PCOS women at risk to develop OHSS.
Phase:
Phase 3
Details
Lead Sponsor:
Centre for Endocrinology and Reproductive Medicine, Italy